ArticleAntibiotics (Basel, Switzerland)2023
Estimation, Evaluation and Characterization of Carbapenem Resistance Burden from a Tertiary Care Hospital, Pakistan.
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Prevalence and antimicrobial resistance trends of ESKAPEE pathogens in clinical isolates from Hyderabad, Pakistan: a cross-sectional study.IJID regions · 2026Article
- Emergence of OXA-48-like Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Hospital Air and Healthcare Personnel as Reservoirs of Drug-Resistant Bacteria in Tertiary Care Settings in Pakistan.Infection and drug resistance · 2026Article
- Patients and Surfaces: Integrated Clinical-Environmental Surveillance of MDR Gram-Negative Bacteria in Critical-Care Units (Karachi, 2024-2025).Microorganisms · 2025Article
- Distribution of MBL and serine-β-lactamase-producing pathogens in ventilator-associated pneumonia: insights into MDR and XDR strains.Iranian journal of microbiology · 2025Article
- Genomic characterization of plasmids harboringMicrobiology spectrum · 2025Article
- Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.BMC infectious diseases · 2025Article
- Resistance trend in bacteria isolated from corneal ulcers: A retrospective analysis from Pakistan.PloS one · 2025Article
- Predominance ofMedicina (Kaunas, Lithuania) · 2024Article
- High-risk clones of carbapenem resistant Klebsiella pneumoniae recovered from pediatric patients in Southern Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- A systematic review and meta-analysis of carbapenem resistance and its possible treatment options with focus on clinicalHeliyon · 2024Article
- Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Multidrug Resistance Profiles and Resistance Mechanisms to β-Lactams and Fluoroquinolones in Bacterial Isolates from Hospital Wastewater in Bangladesh.Current issues in molecular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Carbapenem resistance has become major concern in healthcare settings globally; therefore, its monitoring is crucial for intervention efforts to halt resistance spread. During May 2019-April 2022, 2170 clinical strains were characterized for antimicrobial susceptibility, resistance genes, replicon and sequence types. Overall, 42.1% isolates were carbapenem-resistant, and significantly associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.